thalidomide has been researched along with Experimental Neoplasms in 32 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Thalidomide potentiates etoposide-induced apoptosis in murine neuroblastoma by suppressing NF-κB." | 7.88 | Thalidomide potentiates etoposide-induced apoptosis in murine neuroblastoma through suppression of NF-κB activation. ( Ashizuka, S; Baba, Y; Harada, A; Hiramatsu, T; Kaji, S; Kanamori, D; Miyaguni, K; Ohki, T; Sugihara, T; Uchida, G; Yoshizawa, J, 2018) |
| "Thalidomide has recently been shown to antagonize basic fibroblast growth factor-induced angiogenesis in the rat corneal micropocket assay." | 5.29 | The effect of thalidomide on experimental tumors and metastases. ( Clow, KA; Fryer, KH; Hayes, MM; Minchinton, AI; Wendt, KR, 1996) |
| "Thalidomide potentiates etoposide-induced apoptosis in murine neuroblastoma by suppressing NF-κB." | 3.88 | Thalidomide potentiates etoposide-induced apoptosis in murine neuroblastoma through suppression of NF-κB activation. ( Ashizuka, S; Baba, Y; Harada, A; Hiramatsu, T; Kaji, S; Kanamori, D; Miyaguni, K; Ohki, T; Sugihara, T; Uchida, G; Yoshizawa, J, 2018) |
| "We have previously shown that thalidomide and its potent immunomodulatory derivatives (IMiDs) inhibit the in vitro growth of multiple myeloma (MM) cell lines and patient MM cells that are resistant to conventional therapy." | 3.72 | Immunomodulatory analogs of thalidomide inhibit growth of Hs Sultan cells and angiogenesis in vivo. ( Anderson, KC; Catley, L; Davies, F; Hideshima, T; LeBlanc, R; Lentzsch, S; Lin, B; Podar, K; Stirling, DI, 2003) |
| "Lung cancer is one of the major causes of cancer-related mortality worldwide, and non-small-cell lung cancer is the most common form of lung cancer." | 1.46 | Anticancer effects of novel thalidomide analogs in A549 cells through inhibition of vascular endothelial growth factor and matrix metalloproteinase-2. ( Agwa, H; El-Aarag, B; Kasai, T; Masuda, J; Seno, M; Zahran, M, 2017) |
| "Lenalidomide was evaluated against the PPTP in vitro panel using 96-hr exposure at concentrations ranging from 1 nM to 10 µM." | 1.37 | Initial testing of lenalidomide by the pediatric preclinical testing program. ( Billups, CA; Carol, H; Gorlick, R; Houghton, PJ; Kang, MH; Keir, ST; Kolb, EA; Lock, R; Maris, JM; Morton, CL; Reynolds, CP; Smith, MA, 2011) |
| "Thalidomide has been shown to have anti-angiogenic effects in pre-clinical models as well as a significant antitumor effect in hematologic tumors." | 1.35 | Effects of thalidomide on DMBA-induced oral carcinogenesis in hamster with respect to angiogenesis. ( Ge, JP; Yang, Y; Zhou, ZT, 2009) |
| "Oral treatment of thalidomide or sulindac alone inhibited tumour growth by 55% and 35% respectively." | 1.30 | Combination oral antiangiogenic therapy with thalidomide and sulindac inhibits tumour growth in rabbits. ( D'Amato, RJ; Panigrahy, D; Verheul, HM; Yuan, J, 1999) |
| "Thalidomide has recently been shown to antagonize basic fibroblast growth factor-induced angiogenesis in the rat corneal micropocket assay." | 1.29 | The effect of thalidomide on experimental tumors and metastases. ( Clow, KA; Fryer, KH; Hayes, MM; Minchinton, AI; Wendt, KR, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 17 (53.13) | 18.7374 |
| 1990's | 2 (6.25) | 18.2507 |
| 2000's | 10 (31.25) | 29.6817 |
| 2010's | 3 (9.38) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hiramatsu, T | 1 |
| Yoshizawa, J | 1 |
| Miyaguni, K | 1 |
| Sugihara, T | 1 |
| Harada, A | 1 |
| Kaji, S | 1 |
| Uchida, G | 1 |
| Kanamori, D | 1 |
| Baba, Y | 1 |
| Ashizuka, S | 1 |
| Ohki, T | 1 |
| El-Aarag, B | 1 |
| Kasai, T | 1 |
| Masuda, J | 1 |
| Agwa, H | 1 |
| Zahran, M | 1 |
| Seno, M | 1 |
| Yang, Y | 1 |
| Ge, JP | 1 |
| Zhou, ZT | 1 |
| Zhang, L | 1 |
| Qian, Z | 1 |
| Cai, Z | 1 |
| Sun, L | 1 |
| Wang, H | 1 |
| Bartlett, JB | 1 |
| Yi, Q | 1 |
| Wang, M | 1 |
| Reynolds, CP | 1 |
| Kang, MH | 1 |
| Keir, ST | 1 |
| Gorlick, R | 1 |
| Kolb, EA | 1 |
| Lock, R | 1 |
| Maris, JM | 1 |
| Carol, H | 1 |
| Morton, CL | 1 |
| Billups, CA | 1 |
| Smith, MA | 1 |
| Houghton, PJ | 1 |
| Lentzsch, S | 1 |
| LeBlanc, R | 1 |
| Podar, K | 1 |
| Davies, F | 1 |
| Lin, B | 1 |
| Hideshima, T | 1 |
| Catley, L | 1 |
| Stirling, DI | 1 |
| Anderson, KC | 1 |
| Bauer, JA | 1 |
| Morrison, BH | 1 |
| Grane, RW | 1 |
| Jacobs, BS | 1 |
| Borden, EC | 1 |
| Lindner, DJ | 1 |
| Karrow, NA | 1 |
| Guo, TL | 1 |
| Zhang, LX | 1 |
| McCay, JA | 1 |
| Musgrove, DL | 1 |
| Peachee, VL | 1 |
| Germolec, DR | 1 |
| White, KL | 1 |
| JURET, P | 1 |
| AUBERT, C | 1 |
| DIPAOLO, JA | 1 |
| BACH, A | 2 |
| BICHEL, J | 2 |
| HEJGAARD, JJ | 2 |
| ROE, FJ | 2 |
| MITCHLEY, BC | 1 |
| PAGNINI, G | 1 |
| DICARLO, R | 1 |
| SUGIURA, K | 1 |
| WUEST, HM | 1 |
| Gee, MS | 1 |
| Makonnen, S | 1 |
| al-Kofahi, K | 1 |
| Roysam, B | 1 |
| Payvandi, F | 1 |
| Man, HW | 1 |
| Muller, GW | 1 |
| Lee, WM | 1 |
| Segers, J | 1 |
| Di Fazio, V | 1 |
| Ansiaux, R | 2 |
| Martinive, P | 2 |
| Feron, O | 2 |
| Wallemacq, P | 1 |
| Gallez, B | 2 |
| Murphy, S | 1 |
| Davey, RA | 1 |
| Gu, XQ | 1 |
| Haywood, MC | 1 |
| McCann, LA | 1 |
| Mather, LE | 1 |
| Boyle, FM | 1 |
| Cron, GO | 1 |
| Beghein, N | 1 |
| Blansfield, JA | 1 |
| Caragacianu, D | 1 |
| Alexander, HR | 1 |
| Tangrea, MA | 1 |
| Morita, SY | 1 |
| Lorang, D | 1 |
| Schafer, P | 1 |
| Muller, G | 1 |
| Stirling, D | 1 |
| Royal, RE | 1 |
| Libutti, SK | 1 |
| Braun, AG | 1 |
| Dailey, JP | 1 |
| Minchinton, AI | 1 |
| Fryer, KH | 1 |
| Wendt, KR | 1 |
| Clow, KA | 1 |
| Hayes, MM | 1 |
| Verheul, HM | 1 |
| Panigrahy, D | 1 |
| Yuan, J | 1 |
| D'Amato, RJ | 1 |
| Napalkov, NP | 1 |
| Mückter, H | 2 |
| Moré, E | 1 |
| Rauen, HM | 1 |
| Norpoth, K | 1 |
| Walters, MA | 1 |
| Katsuta, H | 1 |
| Takaoka, T | 1 |
| Miura, M | 1 |
| Southam, CM | 1 |
| Wuest, H | 1 |
| Moiraghi Ruggenini, A | 1 |
| Errigo, E | 1 |
| Chaudhry, AP | 1 |
| Schmutz, JA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase Ib Dose Finding Study of Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765) Plus Lenalidomide / Rituximab in Relapsed or Refractory Mantle Cell Lymphoma (MCL)[NCT02446236] | Phase 1 | 27 participants (Actual) | Interventional | 2015-06-18 | Active, not recruiting | ||
| Study of Pomalidomide in Anal Cancer Precursors (SPACE): a Phase 2 Study of Immunomodulation in People With Persistent HPV-associated High Grade Squamous Intraepithelial Lesions[NCT03113942] | Phase 2 | 26 participants (Actual) | Interventional | 2017-06-14 | Active, not recruiting | ||
| Phase I Study of Bendamustine in Combination With Lenalidomide (CC-5013) and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma[NCT01042704] | Phase 1 | 29 participants (Actual) | Interventional | 2008-02-29 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for thalidomide and Experimental Neoplasms
| Article | Year |
|---|---|
[Transplacental carcinogenesis].
Topics: 9,10-Dimethyl-1,2-benzanthracene; Abnormalities, Drug-Induced; Adenocarcinoma; Animals; Carcinogens; | 1977 |
31 other studies available for thalidomide and Experimental Neoplasms
| Article | Year |
|---|---|
Thalidomide potentiates etoposide-induced apoptosis in murine neuroblastoma through suppression of NF-κB activation.
Topics: Animals; Apoptosis; Cell Line, Tumor; DNA, Neoplasm; Etoposide; Gene Expression Regulation, Neoplast | 2018 |
Anticancer effects of novel thalidomide analogs in A549 cells through inhibition of vascular endothelial growth factor and matrix metalloproteinase-2.
Topics: A549 Cells; Adenocarcinoma; Animals; Apoptosis; Cell Movement; Cell Survival; Female; Gene Expressio | 2017 |
Effects of thalidomide on DMBA-induced oral carcinogenesis in hamster with respect to angiogenesis.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Angiogenesis Inhibitors; Animals; Anticarcinogenic Agents; Carcino | 2009 |
Synergistic antitumor effects of lenalidomide and rituximab on mantle cell lymphoma in vitro and in vivo.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Che | 2009 |
Initial testing of lenalidomide by the pediatric preclinical testing program.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Child; Female; Humans; Lenalid | 2011 |
Immunomodulatory analogs of thalidomide inhibit growth of Hs Sultan cells and angiogenesis in vivo.
Topics: Angiogenesis Inhibitors; Animals; B-Lymphocytes; Female; Humans; Immunosuppressive Agents; Injection | 2003 |
Immunomodulatory analogs of thalidomide inhibit growth of Hs Sultan cells and angiogenesis in vivo.
Topics: Angiogenesis Inhibitors; Animals; B-Lymphocytes; Female; Humans; Immunosuppressive Agents; Injection | 2003 |
Immunomodulatory analogs of thalidomide inhibit growth of Hs Sultan cells and angiogenesis in vivo.
Topics: Angiogenesis Inhibitors; Animals; B-Lymphocytes; Female; Humans; Immunosuppressive Agents; Injection | 2003 |
Immunomodulatory analogs of thalidomide inhibit growth of Hs Sultan cells and angiogenesis in vivo.
Topics: Angiogenesis Inhibitors; Animals; B-Lymphocytes; Female; Humans; Immunosuppressive Agents; Injection | 2003 |
IFN-alpha2b and thalidomide synergistically inhibit tumor-induced angiogenesis.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Cell Division; Drug Administration Schedule | 2003 |
Thalidomide modulation of the immune response in female B6C3F1 mice: a host resistance study.
Topics: Adjuvants, Immunologic; Animals; Bacterial Infections; Dose-Response Relationship, Drug; Female; Imm | 2003 |
[Absence of carcinostatic effect of thalidomide with respect to 2 grafted tumors].
Topics: Animals; Carcinoma; Carcinoma, Ehrlich Tumor; Neoplasms, Experimental; Thalidomide | 1963 |
Effect of thalidomide on a variety of transplantable tumors.
Topics: Neoplasm Transplantation; Neoplasms; Neoplasms, Experimental; Thalidomide | 1963 |
STUDIES ON THE POSSIBLE ANTI-NEOPLASTIC EFFECT OF THALIDOMIDE.
Topics: Adenocarcinoma; Antineoplastic Agents; Leukemia; Leukemia, Experimental; Mice; Neoplasms; Neoplasms, | 1963 |
THALIDOMIDE AND NEOPLASIA.
Topics: Carcinogens; Carcinoma, Hepatocellular; Liver Neoplasms; Lymphoma; Mice; Neoplasms; Neoplasms, Exper | 1963 |
[TREATMENT OF EXPERIMENTAL TUMORS WITH THALIDOMIDE].
Topics: Animals; Carcinoma; Carcinoma, Ehrlich Tumor; Mice; Multiple Myeloma; Neoplasms; Neoplasms, Experime | 1963 |
EFFECT OF THALIDOMIDE ON TRANSPLANTABLE MOUSE, RAT, AND HAMSTER TUMORS.
Topics: Animals; Cricetinae; Infections; Injections; Injections, Intraperitoneal; Leukemia; Leukemia, Experi | 1964 |
[STUDIES IN REGARD TO THE POSSIBLE ANTI-NEOPLASTIC EFFECT OF THALIDOMIDE].
Topics: Antineoplastic Agents; Leukemia; Leukemia, Experimental; Mice; Neoplasms; Neoplasms, Experimental; P | 1963 |
Selective cytokine inhibitory drugs with enhanced antiangiogenic activity control tumor growth through vascular inhibition.
Topics: Angiogenesis Inhibitors; Animals; Cell Division; Cell Hypoxia; Cytokines; Endothelium, Vascular; Mic | 2003 |
Potentiation of cyclophosphamide chemotherapy using the anti-angiogenic drug thalidomide: importance of optimal scheduling to exploit the 'normalization' window of the tumor vasculature.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Alkylating; Chromatography, High Pressure L | 2006 |
Enhancement of cisplatin efficacy by thalidomide in a 9L rat gliosarcoma model.
Topics: Analysis of Variance; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Antineoplastic Combin | 2007 |
19F NMR in vivo spectroscopy reflects the effectiveness of perfusion-enhancing vascular modifiers for improving gemcitabine chemotherapy.
Topics: Animals; Antimetabolites, Antineoplastic; Botulinum Toxins, Type A; Carcinoma, Hepatocellular; Deoxy | 2008 |
Combining agents that target the tumor microenvironment improves the efficacy of anticancer therapy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Cyclo | 2008 |
Thalidomide metabolite inhibits tumor cell attachment to concanavalin A coated surfaces.
Topics: Animals; Cell Adhesion; Cells, Cultured; Concanavalin A; Female; Mice; Mice, Inbred C3H; Microsomes, | 1981 |
The effect of thalidomide on experimental tumors and metastases.
Topics: Animals; Combined Modality Therapy; Female; Mice; Neoplasm Metastasis; Neoplasms, Experimental; Neov | 1996 |
Combination oral antiangiogenic therapy with thalidomide and sulindac inhibits tumour growth in rabbits.
Topics: Administration, Oral; Animals; Cornea; Female; Male; Mice; Mice, Inbred C57BL; Neoplasms, Experiment | 1999 |
[Thalidomide and cancer].
Topics: Animals; Antineoplastic Agents; Benz(a)Anthracenes; Chlormadinone Acetate; Chlorpromazine; Cyclophos | 1966 |
[Growth stimulation by sibliminal concentrations of growth-inhibiting substances].
Topics: Anilides; Animals; Bacteria; Chick Embryo; Dactinomycin; Extraembryonic Membranes; Growth Substances | 1966 |
Sensitivity of newborn mice to carcinogenic agents.
Topics: Adenocarcinoma; Adenoma; Animals; Animals, Newborn; Benz(a)Anthracenes; Carcinogens; Carcinoma, Hepa | 1968 |
Carcinogenesis in tissue culture. 3. Effects of the second treatments on DAB-induced proliferating liver cells of normal rats in culture.
Topics: Animals; Carcinogens; Culture Techniques; Growth Hormone; Liver Neoplasms; Neoplasm Transplantation; | 1965 |
Potentiating effect of thalidomide on methylcholanthrene oncogenesis in mice.
Topics: Animals; Antibody Formation; Cell Count; Cell Transformation, Neoplastic; Drug Synergism; Female; He | 1970 |
[Thalidomide and experimental neoplasms].
Topics: Animals; Antineoplastic Agents; Female; Male; Mice; Neoplasm Transplantation; Neoplasms, Experimenta | 1967 |
Thalidomide and tumor.
Topics: Animals; Antineoplastic Agents; Benz(a)Anthracenes; Female; In Vitro Techniques; Neoplasms, Experime | 1965 |
Effects of prednisolone and thalidomide on induced submandibular gland tumors in hamsters.
Topics: Animals; Benz(a)Anthracenes; Cricetinae; Fibrosarcoma; Neoplasms, Experimental; Prednisolone; Saliva | 1966 |